^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).
Published date:
05/13/2020
Excerpt:
Response rate (RR) in cohort 1 was 71%: CR 1/17 (6%), PR 11/17 (65%), SD 4/17 (23%), 1 never restaged; in cohort 2 RR was 7%: PR 1/14 (7%), SD 7/14 (50%), PD 4/14 (29%), 2 died early.
DOI:
10.1200/JCO.2020.38.15_suppl.6514
Trial ID:
